Towards a precision therapy for Speckle-type POZ protein (SPOP) mutant prostate cancer
This project is funded by the Swiss Krebsliga Association in collaboration with Ruedi Aebersold’s laboratory (ETHZ). The focus of this study is to understand the downstream effectors of SPOP, recurrently mutated in 10% of primary prostate cancer patients, through targeted proteomics, and to help develop clinical biomarkers. Our overarching hypothesis is that SPOP mutant prostate cancer will respond distinctly to targeted therapy due to its inherent vulnerabilities. Other areas of SPOP biology are supported by an NCI grant in its 9th year.
